Neurocrine Biosciences | NBIX - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
AbbVie USD 3.58B 316M 2026-03
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
ALKERMES USD 264.59M 77.4M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amgen USD 1.58B 354M 2026-03
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Cytokinetics USD 104.9M 13.17M 2026-03
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Exelixis USD 139.6M 16.58M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Incyte USD 328.1M 62.31M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Prothena USD 7.65M 5.59M 2025-12
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Repligen USD 76.54M 2.17M 2026-03
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Teva Pharmaceutical Industries USD 1000M 120M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03
Xoma USD 11M 2.54M 2024-06